119 related articles for article (PubMed ID: 9827825)
1. CMV retinitis after cessation of ganciclovir therapy for CMV antigenemia in an unrelated BMT recipient.
Suzuki N; Kudoh T; Mizue N; Watanabe J; Ikehata M; Tateno M; Ooguro H; Chiba S
Bone Marrow Transplant; 1998 Nov; 22(9):931-2. PubMed ID: 9827825
[TBL] [Abstract][Full Text] [Related]
2. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
Okamoto T; Okada M; Mori A; Saheki K; Takatsuka H; Wada H; Tamura A; Fujimori Y; Takemoto Y; Kanamaru A; Kakishita E
Bone Marrow Transplant; 1997 Nov; 20(9):801-3. PubMed ID: 9384487
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation.
Kaulfersch W; Urban C; Hauer C; Lackner H; Gamillscheg A; Slavc I; Langmann G
Bone Marrow Transplant; 1989 Sep; 4(5):587-9. PubMed ID: 2551437
[TBL] [Abstract][Full Text] [Related]
5. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
6. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
[TBL] [Abstract][Full Text] [Related]
7. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study.
Boeckh M; Gooley TA; Myerson D; Cunningham T; Schoch G; Bowden RA
Blood; 1996 Nov; 88(10):4063-71. PubMed ID: 8916975
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation.
Sakamaki H; Yuasa K; Goto H; Tanikawa S; Akiyama H; Onozawa Y; Okamoto R; Maeda Y; Sasaki T; Kaku H; Tsuzuki S; Takamoto S; Mochida Y; Minematsu T; Minamishima Y
Bone Marrow Transplant; 1997 Jul; 20(2):143-7. PubMed ID: 9244418
[TBL] [Abstract][Full Text] [Related]
12. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
[TBL] [Abstract][Full Text] [Related]
13. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
[TBL] [Abstract][Full Text] [Related]
14. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy.
Koehler M; St George K; Ehrlich GD; Mirro J; Neudorf SM; Rinaldo C
J Pediatr Hematol Oncol; 1997; 19(1):43-7. PubMed ID: 9065718
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
[TBL] [Abstract][Full Text] [Related]
16. Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation.
Ghosh K; Muirhead D; Christie B; Hiwase D
Bone Marrow Transplant; 1999 Aug; 24(4):429-31. PubMed ID: 10467335
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT.
Kanda Y; Yamashita T; Mori T; Ito T; Tajika K; Mori S; Sakura T; Hara M; Mitani K; Kurokawa M; Akashi K; Harada M
Bone Marrow Transplant; 2010 Aug; 45(8):1325-32. PubMed ID: 19966850
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Humar A; O'Rourke K; Lipton J; Messner H; Meharchand J; Mahony J; Walker I; Wasi P; McGeer A; Moussa G; Chua R; Mazzulli T
Bone Marrow Transplant; 1999 Jan; 23(1):45-51. PubMed ID: 10037050
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia.
Kuriyama K; Todo S; Ikushima S; Fujii N; Yoshihara T; Tsunamoto K; Naya M; Hojo M; Hibi S; Morimoto A; Imashuku S
Int J Hematol; 2001 Dec; 74(4):455-60. PubMed ID: 11794704
[TBL] [Abstract][Full Text] [Related]
20. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
